Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids

J Inherit Metab Dis. 2002 May;25(2):119-25. doi: 10.1023/a:1015624726822.

Abstract

Congenital microcephaly, intractable seizures and severe psychomotor retardation characterize 3-phosphoglycerate dehydrogenase (3-PGDH) deficiency, a disorder of L-serine biosynthesis. The enzyme defect results in low concentrations of serine and to a variable degree of glycine in plasma and cerebrospinal fluid. Short-term beneficial effects have been reported of oral treatment with the deficient amino acids. In this paper, we report the first follow-up data of amino acid therapy in five patients treated for 3-7.5 years. Different treatment regimes were used, but a favourable response to amino acids was observed in all patients. A major reduction in seizure frequency occurred in all patients; two patients became free of seizures. Amino acids were well tolerated and no adverse effects were documented. A progress of psychomotor development was only observed in one patient, diagnosed early and treated with a high dosage of L-serine. A favourable outcome of 3-PGDH deficiency depends on early diagnosis and treatment.

Publication types

  • Case Reports

MeSH terms

  • Carbohydrate Dehydrogenases / deficiency*
  • Child
  • Child, Preschool
  • Female
  • Glycine / blood
  • Glycine / cerebrospinal fluid
  • Humans
  • Infant
  • Male
  • Microcephaly / genetics*
  • Phosphoglycerate Dehydrogenase
  • Psychomotor Disorders / genetics
  • Seizures / drug therapy
  • Seizures / genetics*
  • Serine / blood
  • Serine / cerebrospinal fluid
  • Serine / therapeutic use*
  • Treatment Outcome

Substances

  • Serine
  • Carbohydrate Dehydrogenases
  • Phosphoglycerate Dehydrogenase
  • Glycine